138
Participants
Start Date
November 30, 2015
Primary Completion Date
April 26, 2018
Study Completion Date
May 18, 2018
High-titer anti-influenza plasma
Human plasma (FFP or FP24, 225-350 mL per unit or pediatric equivalent) with both an influenza A/H1N1 and A/H3N2 HAI titer of at least 1:80
Low-titer anti-influenza plasma
Human plasma (FFP or FP24, 225-350 mL per unit or pediatric equivalent) with both an influenza A/H1N1 and A/H3N2 HAI titer of 1:10 or less
New York University/Bellevue Hospital, New York
University of Pittsburgh Medical Center, Pittsburgh
University of Pennsylvania, Philadelphia
University of Maryland Medical Center, Baltimore
Johns Hopkins University, Baltimore
Duke University, Durham
Carolinas Medical Center, Charlotte
University of Florida, Gainesville
Cincinnati Children's Hospital Medical Center, Cincinnati
University of Cincinnati, Cincinnati
Beaumont Hospital - Royal Oak, Royal Oak
Beaumont Hospital, Troy, Troy
University of Michigan, Ann Arbor
Mayo Clinic Campus Saint Mary's, Rochester
Rush University Medical Center, Chicago
St. Louis Children's Hospital at Washington University, St Louis
Creighton University Medical Center, Omaha
University of Oklahoma Health Sciences Center, Oklahoma City
UT Southwestern Medical Center, Dallas
Children's Hospital Colorado, Aurora
University of Colorado Denver, Aurora
University of Arizona Health Sciences Center, Tucson
Naval Medical Center San Diego (NMCSD), San Diego
Madigan Army Medical Center (MAMC), Tacoma
UCLA Pediatrics Infectious Diseases, Los Angeles
Bridgeport Hospital, Bridgeport
Massachusetts General Hospital, Boston
Boston Children's Hospital, Boston
University of Massachusetts Medical School, Worcester
University of Vermont, Burlington
National Institute of Allergy and Infectious Diseases (NIAID)
NIH